239 related articles for article (PubMed ID: 32818320)
1. Loss of the cystine/glutamate antiporter in melanoma abrogates tumor metastasis and markedly increases survival rates of mice.
Sato M; Onuma K; Domon M; Hasegawa S; Suzuki A; Kusumi R; Hino R; Kakihara N; Kanda Y; Osaki M; Hamada J; Bannai S; Feederle R; Buday K; Angeli JPF; Proneth B; Conrad M; Okada F; Sato H
Int J Cancer; 2020 Dec; 147(11):3224-3235. PubMed ID: 32818320
[TBL] [Abstract][Full Text] [Related]
2. xCT knockdown in human breast cancer cells delays onset of cancer-induced bone pain.
Ungard RG; Linher-Melville K; Nashed MG; Sharma M; Wen J; Singh G
Mol Pain; 2019; 15():1744806918822185. PubMed ID: 30799686
[TBL] [Abstract][Full Text] [Related]
3. xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling.
Liu J; Xia X; Huang P
Mol Ther; 2020 Nov; 28(11):2358-2366. PubMed ID: 32931751
[TBL] [Abstract][Full Text] [Related]
4. Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models.
Ruiu R; Cossu C; Iacoviello A; Conti L; Bolli E; Ponzone L; Magri J; Rumandla A; Calautti E; Cavallo F
J Exp Clin Cancer Res; 2023 Sep; 42(1):254. PubMed ID: 37770957
[TBL] [Abstract][Full Text] [Related]
5. High-Throughput Assay Development for Cystine-Glutamate Antiporter (xc-) Highlights Faster Cystine Uptake than Glutamate Release in Glioma Cells.
Thomas AG; Sattler R; Tendyke K; Loiacono KA; Hansen H; Sahni V; Hashizume Y; Rojas C; Slusher BS
PLoS One; 2015; 10(8):e0127785. PubMed ID: 26252954
[TBL] [Abstract][Full Text] [Related]
6. Cystine-glutamate antiporter xCT as a therapeutic target for cancer.
Liu L; Liu R; Liu Y; Li G; Chen Q; Liu X; Ma S
Cell Biochem Funct; 2021 Mar; 39(2):174-179. PubMed ID: 32749001
[TBL] [Abstract][Full Text] [Related]
7. Absence of system x
Merckx E; Albertini G; Paterka M; Jensen C; Albrecht P; Dietrich M; Van Liefferinge J; Bentea E; Verbruggen L; Demuyser T; Deneyer L; Lewerenz J; van Loo G; De Keyser J; Sato H; Maher P; Methner A; Massie A
J Neuroinflammation; 2017 Jan; 14(1):9. PubMed ID: 28086920
[TBL] [Abstract][Full Text] [Related]
8. Establishment of SLC7A11-knockout mouse and its preliminary investigation in melanoma.
Chen Y; Lu T; Liu Y; Liu Y; Bai S; Chen Q; Zhao B; Wu X
In Vitro Cell Dev Biol Anim; 2023 Oct; 59(9):729-737. PubMed ID: 37932516
[TBL] [Abstract][Full Text] [Related]
9. Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance.
Polewski MD; Reveron-Thornton RF; Cherryholmes GA; Marinov GK; Cassady K; Aboody KS
Mol Cancer Res; 2016 Dec; 14(12):1229-1242. PubMed ID: 27658422
[TBL] [Abstract][Full Text] [Related]
10. The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine.
Guan J; Lo M; Dockery P; Mahon S; Karp CM; Buckley AR; Lam S; Gout PW; Wang YZ
Cancer Chemother Pharmacol; 2009 Aug; 64(3):463-72. PubMed ID: 19104813
[TBL] [Abstract][Full Text] [Related]
11. Slc7a11 (xCT) protein expression is not altered in the depressed brain and system xc- deficiency does not affect depression-associated behaviour in the corticosterone mouse model.
Demuyser T; Deneyer L; Bentea E; Albertini G; Femenia T; Walrave L; Sato H; Danbolt NC; De Bundel D; Michotte A; Lindskog M; Massie A; Smolders I
World J Biol Psychiatry; 2019 Jun; 20(5):381-392. PubMed ID: 28882088
[No Abstract] [Full Text] [Related]
12. Interleukin 1β Regulation of the System xc- Substrate-specific Subunit, xCT, in Primary Mouse Astrocytes Involves the RNA-binding Protein HuR.
Shi J; He Y; Hewett SJ; Hewett JA
J Biol Chem; 2016 Jan; 291(4):1643-1651. PubMed ID: 26601945
[TBL] [Abstract][Full Text] [Related]
13. Functional effects of TrkA inhibition on system x
Miladinovic T; Ungard RG; Linher-Melville K; Popovic S; Singh G
Mol Pain; 2018; 14():1744806918776467. PubMed ID: 29761734
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling.
Suina K; Tsuchihashi K; Yamasaki J; Kamenori S; Shintani S; Hirata Y; Okazaki S; Sampetrean O; Baba E; Akashi K; Mitsuishi Y; Takahashi F; Takahashi K; Saya H; Nagano O
Cancer Sci; 2018 Dec; 109(12):3874-3882. PubMed ID: 30298963
[TBL] [Abstract][Full Text] [Related]
15. System Xc
Liu MR; Zhu WT; Pei DS
Invest New Drugs; 2021 Aug; 39(4):1123-1131. PubMed ID: 33506324
[TBL] [Abstract][Full Text] [Related]
16. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway.
Chen RS; Song YM; Zhou ZY; Tong T; Li Y; Fu M; Guo XL; Dong LJ; He X; Qiao HX; Zhan QM; Li W
Oncogene; 2009 Jan; 28(4):599-609. PubMed ID: 19015640
[TBL] [Abstract][Full Text] [Related]
17. xCT (SLC7A11) expression confers intrinsic resistance to physical plasma treatment in tumor cells.
Bekeschus S; Eisenmann S; Sagwal SK; Bodnar Y; Moritz J; Poschkamp B; Stoffels I; Emmert S; Madesh M; Weltmann KD; von Woedtke T; Gandhirajan RK
Redox Biol; 2020 Feb; 30():101423. PubMed ID: 31931281
[TBL] [Abstract][Full Text] [Related]
18. IFNγ-mediated repression of system xc
Kong R; Wang N; Han W; Bao W; Lu J
J Leukoc Biol; 2021 Aug; 110(2):301-314. PubMed ID: 34318944
[TBL] [Abstract][Full Text] [Related]
19. The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate.
Koppula P; Zhang Y; Shi J; Li W; Gan B
J Biol Chem; 2017 Aug; 292(34):14240-14249. PubMed ID: 28630042
[TBL] [Abstract][Full Text] [Related]
20. Behavioral characterization of system xc- mutant mice.
McCullagh EA; Featherstone DE
Behav Brain Res; 2014 May; 265():1-11. PubMed ID: 24548853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
